Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528567 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178698 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401258 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29359997 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL178733 | 1.00 | KMT2A (0.66) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29423590 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL29401604 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119708 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL18148920 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 | |
| SCHEMBL119709 | 0.97 | KMT2A (0.64) | KMT2AMDM2MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| US-20250282820-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | PEPTIDREAM INC (JP) | 2025-09-11 | — | — | US | disclosed |
| EP-4501941-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | PeptiDream Inc. (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | PEPTIAID INC (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4317174-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | Peptiaid Inc (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-05-25 | — | — | US | disclosed |
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2022-06-16 | — | — | US | disclosed |
| EP-3946363-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | Novo Nordisk A/S (DK) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020201041-A2 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | WO | disclosed |
| WO-2017205336-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170049780-A1 | USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN | US HEALTH (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170049780-A1 | USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN | US HEALTH (US) | 2017-02-23 | — | — | US | disclosed |
| WO-2015106599-A1 | CONJUGATES AND COMPOSITIONS FOR DRUG DELIVERY | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2015-07-23 | — | — | WO | disclosed |
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2009-12-17 | — | — | US | disclosed |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2009-12-17 | — | — | US | disclosed |
| US-7479495-B2 | N-heterocyclic inhibitors of TNF-α expression | PHARMACOPEIA, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2008072933-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI -AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184184-A1 | GLUCOSE SENSITIVE INSULIN DERIVATIVES | IAPP, IRS1, GPR119 | KMT2A 4867/4885MDM2 381/4885MDM4 2541/4885 |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | NPPA, PARN, PARG | KMT2A 548/4885MDM2 4422/4885MDM4 2068/4885 |
| US-20170049780-A1 | USE OF (2R, 6R)-HYDROXYNORKETAMINE, (S)-DEHYDRONORKETAMINE AND OTHER STEREOISOMERIC DEHYDRO AND HYDROXYLATED METABOLITES OF (R,S)- KETAMINE IN THE TREATMENT OF DEPRESSION AND NEUROPATHIC PAIN | CYP2D6, GRIN2D, OPRD1 | KMT2A 1009/4885MDM2 3924/4885MDM4 3906/4885 |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KMT2A 3715/4885MDM2 1169/4885MDM4 2010/4885 |
| US-20240209027-A1 | PEPTIDE AND PEPTIDE-CONTAINING COMPOSITION | NGLY1, VIP, HM13 | KMT2A 2534/4885MDM2 3700/4885MDM4 973/4885 |
| US-20250282820-A1 | PEPTIDE COMPLEX HAVING TRKB BINDING ACTIVITY | NTRK2, BDNF, NPY1R | KMT2A 1556/4885MDM2 3088/4885MDM4 4384/4885 |
| US-20230160000-A1 | SYNTHESIS OF NOVEL DISULFIDE LINKER BASED NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCING BY SYNTHESIS | POLRMT, RNGTT, MTR | KMT2A 1610/4885MDM2 3408/4885MDM4 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.